Lung cancer remains among the world’s most frequently diagnosed and deadly cancers. Although screening programs and targeted therapies have improved outcomes for some patients, major challenges persist. Early-stage disease can be difficult to distinguish from benign abnormalities, tumors can vary dramatically between patients, and the same tumor may evolve during treatment. Conventional clinical workflows often depend heavily on expert interpretation and incomplete snapshots of disease biology. A scan may reveal the shape of a lesion but not fully explain its molecular behavior; a biopsy may identify cancer cells but miss important differences between regions of the tumor; and a blood test may capture circulating signals that are invisible in tissue. Machine learning offers a way to combine these partial views and identify patterns that may be too subtle, multidimensional, or time-dependent for unaided human analysis.

The review was prepared by researchers from Shanghai Jiao Tong University, Qilu Hospital of Shandong University, Chongqing Medical University, and related institutions. The team organizes the field around a simple but powerful chain: data characteristics determine model selection, model performance determines the reliability of predictions, and reliable predictions must ultimately demonstrate clinical value. Five major data sources form the foundation of this framework. Medical imaging contributes information about tumor size, shape, density, texture, location, and changes over time. Multi-omics data—including genomics, transcriptomics, proteomics, and metabolomics—describe the molecular programs associated with tumor development and treatment response. Liquid biopsy can provide minimally invasive signals from circulating tumor DNA, RNA, proteins, or cells. Digital pathology captures cellular architecture at microscopic resolution, while clinical records provide demographic, physiological, treatment, and outcome information.

Each data type presents a different computational challenge. Imaging data are often high-dimensional and spatially structured, making convolutional neural networks and other deep-learning architectures useful for detecting features across pixels or three-dimensional scans. Digital pathology images can contain billions of pixels, requiring systems that divide slides into smaller regions before learning how local cellular patterns relate to a patient’s diagnosis or prognosis. Omics datasets, by contrast, may contain thousands of molecular variables but relatively few patient samples, creating a high risk of overfitting. Traditional machine-learning methods, feature selection, regularization, and dimensionality-reduction techniques can be valuable in such settings because they constrain the model and make its predictions more stable. Clinical data may include missing values, inconsistent terminology, and irregular time points, requiring specialized preprocessing and models capable of handling longitudinal information.

The article compares several generations of machine-learning approaches. Traditional methods such as logistic regression, support-vector machines, random forests, and gradient-boosting algorithms can perform well when datasets are moderate in size and features have been carefully defined. They are often easier to validate and interpret than more complex systems. Deep learning can learn representations directly from raw images, pathology slides, or other unstructured data, reducing the need for manual feature engineering. However, deep models generally require large, diverse, and consistently labeled datasets. Multimodal fusion methods attempt to combine information from different sources, either by integrating features early in the computational pipeline, merging model outputs at a later stage, or using architectures that learn relationships between modalities. These approaches can capture complementary signals, but they also face the problem of missing or poorly aligned data.

Foundation models represent another emerging direction. Trained on very large datasets, these models can learn general biological or visual representations and then be adapted to particular lung cancer tasks with less task-specific data. In principle, a foundation model trained on broad medical images or pathology material could be fine-tuned for nodule classification, tumor segmentation, subtype recognition, or treatment-response prediction. Yet the review emphasizes that scale alone does not guarantee clinical reliability. Training data may reflect one hospital, one scanner type, one population, or one style of clinical documentation. A model can therefore appear highly accurate in development while failing when transferred to a different institution. External validation, calibration, transparent reporting, and continuous monitoring are essential before such systems can influence patient care.

In early detection and diagnosis, multi-source machine learning could help clinicians distinguish malignant nodules from benign findings, prioritize patients for further testing, and identify cancers that might otherwise be overlooked. Imaging models can analyze subtle radiological patterns, including texture and spatial relationships that are difficult to describe using conventional measurements. When imaging is combined with clinical information, smoking history, laboratory results, or molecular signals from blood, the resulting prediction may be more informative than any single source alone. Similar strategies could support pathological diagnosis by linking tissue morphology with molecular subtypes and clinical outcomes. The aim is not simply to automate a radiologist’s or pathologist’s work, but to provide additional evidence, reduce variation, and help specialists focus attention on ambiguous or high-risk cases.

Treatment selection is another major area of opportunity. Lung cancer includes biologically distinct diseases that can respond very differently to surgery, chemotherapy, radiotherapy, targeted drugs, or immunotherapy. Machine-learning models can search for associations between molecular alterations, imaging features, pathological characteristics, treatment histories, and outcomes. These analyses may help estimate the probability that a patient will benefit from a particular therapy or develop resistance. Repeated measurements also make it possible to track disease dynamically. Changes in circulating tumor DNA, radiological appearance, or laboratory indicators could be analyzed over time to detect treatment response earlier than traditional assessments. Such systems could support adaptive treatment strategies, although the review stresses that predictions must be tested in prospective clinical studies rather than accepted solely on the basis of retrospective datasets.

Prognosis is similarly moving from a single end-of-treatment estimate toward continuous risk assessment. By integrating tumor biology, disease stage, treatment response, comorbidities, and follow-up information, machine-learning systems may identify patients at different risks of recurrence, progression, or treatment-related complications. This could allow surveillance schedules and supportive care to be tailored more precisely. However, the review identifies several barriers between promising algorithms and routine clinical use. Data standards remain inconsistent across hospitals; imaging protocols and pathology procedures vary; omics measurements can be expensive and technically heterogeneous; and patient records frequently contain missing or biased information. Multimodal models may also become less reliable when one data source is unavailable. In addition, clinicians and patients need to understand why a model produces a recommendation, especially when that recommendation affects an invasive procedure or life-changing therapy.

The researchers propose that future progress should focus on standardized data collection, adaptive fusion of complementary modalities, interpretable artificial intelligence, and prospective validation in real clinical environments. Interpretability does not necessarily mean reducing a complex model to a simple formula. It may involve showing which image regions influenced a prediction, identifying the molecular features associated with risk, quantifying uncertainty, or explaining how a patient’s current result differs from comparable cases. Fairness and privacy will also be central as hospitals connect large datasets and develop shared learning systems. Techniques such as federated learning could allow institutions to train models without transferring raw patient records, while robust governance frameworks could define how algorithms are audited, updated, and held accountable. The long-term vision presented in the review is a closed-loop lung cancer system in which early screening, diagnosis, personalized treatment, and prognosis are connected through continuously updated evidence. If that vision can be translated safely into practice, machine learning may help shift lung cancer management from experience-driven decisions toward precise, dynamic, and patient-specific care.

Subject of Research: Multi-source data-driven machine learning applications in lung cancer diagnosis, treatment, and prognosis.

Article Title: “Multi-source data-driven machine learning for lung cancer: diagnosis, treatment, and prognosis”

News Publication Date: 29 June 2026

Web References: https://doi.org/10.67704/ioe.2026.260006

References: Original review published in Intelligent Opto-Electronics, DOI: 10.67704/ioe.2026.260006.

Image Credits: Editorial Office of Opto-Electronic Journals Group.

Keywords: Lung cancer, machine learning, artificial intelligence, multimodal data, medical imaging, multi-omics, liquid biopsy, digital pathology, precision medicine, prognosis.

The appeal of AI in medicine is rooted in its ability to process information at a scale no individual clinician can match. Modern health care generates enormous quantities of data, including electronic health records, laboratory measurements, medication histories, medical images, genetic sequences, wearable-device signals and clinical notes. Machine-learning systems can analyze these data rapidly, identify statistical patterns and generate predictions about diagnosis, prognosis or treatment response. In imaging, neural networks can be trained to recognize subtle features associated with cancer, retinal disease or neurological injury. In clinical documentation, large language models can summarize records, draft notes and extract relevant information from thousands of pages. These capabilities could reduce delays and help clinicians detect signals that might otherwise be overlooked.

AI systems may also make medical expertise more continuously available. A physician can examine only a limited number of patients at a time, while software can operate around the clock and support millions of interactions simultaneously. Automated tools could answer routine questions, monitor chronic conditions, remind patients about medications and identify changes that warrant professional attention. For people living in regions with few doctors, algorithmic systems might provide preliminary guidance or help local health workers interpret complex cases. In principle, AI could also reduce costs by automating repetitive administrative work, allowing physicians to spend more time on diagnosis, communication and treatment decisions. The technology’s greatest value may therefore come not from replacing clinical encounters but from extending the reach of scarce medical expertise.

Yet speed and scale do not guarantee safe or appropriate care. AI models learn from existing data, and those data reflect the strengths, weaknesses and inequities of the health systems that produced them. If a training dataset contains fewer examples from particular racial, ethnic, socioeconomic or geographic groups, an algorithm may perform less accurately for those patients. A model developed in one hospital may fail when deployed in another because patient populations, equipment, documentation practices and disease prevalence differ. This problem, known as distribution shift, can cause performance to deteriorate when real-world conditions depart from the environment in which the system was trained. Continuous monitoring, external validation and recalibration are therefore essential, but they are technically demanding and often neglected after deployment.

AI also introduces distinctive forms of error. A language model can produce fluent but false statements, a phenomenon commonly called hallucination. A diagnostic algorithm may be highly accurate on average while making dangerous mistakes in unusual cases. Some systems provide a probability without explaining the biological or clinical reasoning behind it, making it difficult for a physician or patient to challenge the recommendation. Other models can be influenced by irrelevant details, such as differences in image quality or wording in a clinical note. Automation bias adds another risk: people may accept a computer-generated recommendation simply because it appears objective or technologically sophisticated. In medicine, an incorrect answer delivered with confidence can be more hazardous than an acknowledged uncertainty.

Physician-led care has limitations of its own. Doctors vary in knowledge, experience, attention and susceptibility to cognitive biases. Fatigue, time pressure and excessive workloads can contribute to diagnostic mistakes, delayed follow-up and communication failures. Human clinicians may also rely too heavily on familiar patterns, overlook rare conditions or recommend treatments inconsistently. Medical care can be expensive and difficult to access, particularly for patients who live far from hospitals or lack insurance. Physicians cannot memorize every new study, guideline or drug interaction, and no doctor can independently review all the information available in a complex patient record. These constraints explain why AI tools are attractive even to clinicians who remain cautious about autonomous medical decision-making.

The central distinction is not simply between human intelligence and artificial intelligence, but between different kinds of judgment. Physicians can interpret a patient’s goals, fears, family circumstances and tolerance for risk in ways that remain difficult to encode mathematically. They can notice when a patient’s words, behavior or silence suggests distress, confusion or mistrust. They can negotiate competing values, explain uncertainty and accept responsibility for a recommendation. These interpersonal and ethical dimensions are not peripheral to medicine; they influence whether patients understand a diagnosis, follow a treatment plan and feel respected. AI can imitate empathy through language, but imitation does not necessarily equal comprehension, moral responsibility or a genuine therapeutic relationship.

A safer model may be collaborative care in which algorithms perform narrowly defined tasks while physicians retain meaningful oversight. In such a system, AI might screen images, identify medication interactions, compare a patient’s data with relevant evidence or alert clinicians to a deteriorating condition. The physician would evaluate the output in context, discuss options with the patient and decide whether the recommendation is appropriate. This arrangement, however, requires more than placing a software tool inside a hospital. Clinicians must be trained to understand model limitations, interpret confidence scores and recognize when an algorithm is operating outside its validated range. Health systems also need clear rules for documenting AI involvement, investigating errors and determining responsibility when automated advice contributes to harm.

The expansion of AI care raises broader questions about accountability, privacy and the future medical workforce. Training powerful models requires access to sensitive health information, creating risks if data are collected without meaningful consent or protected inadequately. Commercial systems may be difficult to audit if their developers treat model architecture or training data as proprietary. Patients may not know whether they are communicating with a person or a machine, or how their information will be used to improve the system. At the same time, widespread automation could change the skills expected of physicians, shifting emphasis from memorization toward verification, communication, systems thinking and ethical reasoning. The Perspective in JAMA presents this debate as a choice with no effortless answer: AI may improve accuracy, access and efficiency, but medicine’s human obligations cannot be reduced to prediction alone. The future of care will depend on whether technological power is placed under effective clinical, ethical and public oversight.

Subject of Research: The advantages and disadvantages of physician-led medical care compared with medical care provided by artificial intelligence.

Web References: https://doi.org/10.1001/jama.2026.15380

References: Emanuel EJ. Perspective on physician-led medical care versus artificial intelligence–provided medical care. JAMA. doi:10.1001/jama.2026.15380.

Keywords

Artificial intelligence; AI in medicine; physician-led care; health care; clinical decision-making; machine learning; medical ethics; diagnostic accuracy; patient safety; health equity.

The comprehensive study scrutinized a massive dataset derived from Epic electronic health records, the most widely utilized system across U.S. hospitals and clinics. Analyzing more than 140 million patient records spanning 2,067 hospitals and 47,100 outpatient clinics, researchers evaluated over 8 billion documented interactions between patients and providers covering the period from January 2020 through December 2025. The findings provide unprecedented insights into the pandemic-driven acceleration and normalization of digital healthcare communications.

Published online in the Journal of the American Medical Association (JAMA) on June 22, 2026, the study reveals that patient messages routed through online portals more than doubled during this five-year window, increasing by a striking 153 percent. In stark contrast, traditional telephone communications decreased by 6 percent, signaling a fundamental shift in patient preference for digital messaging platforms over phone calls when managing appointments, test results, and ongoing treatments. Concurrently, the number of Americans with active Epic health records surged from 94 million in 2020 to 140 million in 2025, underscoring the rapid adoption of digital healthcare infrastructure nationwide.

Interestingly, the rise in digital portal usage has not come at the expense of in-person medical appointments. Instead, visits to healthcare providers have rebounded robustly since the pandemic’s height, stabilizing at an average of two to three office visits per patient annually. This coexistence of digital and physical care modalities suggests a hybrid model of healthcare delivery is emerging — one that enhances patient access and convenience while preserving the clinical benefits of face-to-face consultations.

The volume of patient-initiated messages has escalated sharply, with average annual communications rising from 2.2 per patient in early 2020 to 5.4 by late 2025. Senior investigator Michal A. Mankowski, PhD, assistant professor in the Department of Surgery at NYU Grossman School of Medicine, emphasized the significance of these findings, stating that digital health tools have become ingrained in everyday patient care rather than being peripheral or adjunct options. The increased accessibility to physicians and clinical staff suggests a shift toward more continuous, untethered healthcare interactions, no longer confined to scheduled appointments within traditional office hours.

Importantly, this new digital-first communication paradigm introduces additional operational complexity for healthcare providers. Co-investigator Dorry L. Segev, MD, PhD, professor and vice chair in Surgery at NYU Grossman, explained that digital workflows add layered demands atop established clinical duties. This necessitates forward-looking staffing strategies and innovative support systems to sustain provider efficiency and prevent burnout. Effective integration of messaging platforms, electronic clinical notes, online billing, and remote counseling are critical components in redesigning provider workflows for the digital age.

Dr. Segev highlighted the growing role of artificial intelligence in facilitating these transitions. NYU Langone is already implementing AI tools that expedite the drafting of clinical documentation and streamline provider communications, indicating a rapidly evolving technological ecosystem supporting modern medicine. AI-powered chatbots and content framing systems can reduce message complexity, enabling clinicians to focus on higher-value tasks while maintaining high-quality patient engagement and care continuity.

The vast scale and granularity of the Epic Cosmos dataset underpinning the study is notable. Covering over 300 million American patients’ records from a majority of Epic-using institutions, this repository offers a unique vantage point to analyze national healthcare trends. Despite Epic’s role as the largest electronic health record vendor, the study was conducted independently, with the company playing no direct role in data analysis to ensure scientific rigor and impartiality.

Beyond confirming the marked increase in digital communications, the study quantified interaction volumes: between 2020 and 2025, patients booked at least 1.77 billion in-person visits through Epic systems, sent 1.34 billion messages to providers, and received 3.25 billion portal messages in return. Telephone calls totaled 1.59 billion, with 146 million telehealth video visits logged, illustrating the multiplicity of engagement channels coexisting in contemporary healthcare delivery.

Looking ahead, the NYU Langone research team plans to delve deeper into regional and outpatient clinic-specific digital usage trends. This next phase aims to generate actionable insights capable of informing operational planning, resource allocation, and the customization of digital health services according to local healthcare ecosystem characteristics.

This pioneering study affords a valuable roadmap for healthcare systems navigating the digital transformation prompted by the COVID-19 pandemic and sustained technological advances. By demonstrating how patients and providers seamlessly integrate online messaging and portals with conventional visits, the research heralds a new era in which healthcare is increasingly continuous, accessible beyond office hours, and optimized through technological augmentation.

NYU Langone Health, the study’s home institution, is recognized nationally for outstanding clinical outcomes and academic leadership. The health system comprises multiple inpatient facilities, specialty centers such as the Perlmutter Cancer Center, and over 330 outpatient sites throughout New York and Florida. NYU Langone’s integration of cutting-edge digital tools exemplifies its commitment to innovation in patient care delivery.

This comprehensive investigation not only offers strategic insights to hospital administrators and clinicians but also highlights the imperative for training healthcare professionals to effectively navigate burgeoning digital workflows. Mastery of patient messaging platforms, AI-assisted documentation, and virtual counseling is fast becoming a core competency in modern medical practice.

In summary, the study presents a compelling portrait of a healthcare landscape in flux — one where the patient-provider relationship has expanded its temporal and spatial boundaries through secure online portals, while in-person care remains indispensable. The dual rise of digital and physical engagements reflects a balanced, hybrid model with transformative potential to enhance healthcare access, efficiency, and patient satisfaction across the United States.

Subject of Research: People
Article Title: Trends in Patient Portal Messages, Office Visits, and Telephone Encounters
News Publication Date: 22-Jun-2026
Web References: http://dx.doi.org/10.1001/jama.2026.8690
References: Journal of the American Medical Association (JAMA), 10.1001/jama.2026.8690
Keywords: Electronic medical records, Informatics

At the heart of this investigation lies an unsettling recognition: relying solely on diagnosis codes grossly underestimates the prevalence of self-harm, a risk factor intrinsic to predicting future suicide and guiding therapeutic interventions. Dr. Christophe Lambert, the study’s principal investigator and expert in translational informatics, emphasized that this “visibility gap” not only hampers research accuracy but also impedes clinical vigilance and resource allocation. Traditional coding is streamlined for ease, but the toll it extracts from subtle, narrative-rich notes within EHRs leaves many patients’ critical histories hidden from immediate view.

The study, published in the Journal of Medical Internet Research, utilized an advanced machine learning framework to penetrate this opacity. Unlike conventional approaches requiring definitive case and control groups, the team deployed a method known as Positive and Unlabeled Learning Selected Not At Random (PULSNAR). This technique excels in the chaotic terrain of real-world data, where the absence of a diagnostic code does not guarantee the absence of the condition itself. Instead, PULSNAR models the probability that certain patients possess an extensive but uncoded history of self-harm, capturing nuanced patterns from both coded records and the unstructured clinical notes that typify physician documentation.

Self-harm is more than a distressing event—its undocumented presence in EHRs poses a persistent risk for subsequent psychiatric crises, compounded by co-occurring disorders such as depression, post-traumatic stress disorder (PTSD), bipolar disorder, substance use disorders, and traumatic brain injury. These overlapping clinical landscapes necessitate complete, timely visibility of patient histories to inform both tailored treatment plans and system-wide mental health strategies. Unfortunately, even aggregations designed for clinical summation, such as problem lists, suffer from inconsistency and incompleteness. The research revealed that only approximately 22.6% of veterans with coded self-harm histories had this critical information reflected in their problem lists, further obscuring the data from those on the frontlines of care.

The implications of these gaps extend beyond individual clinical encounters to the broader realm of health services research and policy-making. Misclassification or undercounting of self-harm due to deficient coding can distort epidemiological insights and the allocation of limited mental health resources. Given that some EHRs in the study contained over half a million lines of clinical notes per patient, expecting individual clinicians to sift through this vast repository during routine visits is impractical. The reliance on codified data facilitates large-scale analysis but risks excluding a critical subset of patients due to documentation nuances.

The innovative machine learning approach employed in this study exemplifies a pivotal advance in health informatics. PULSNAR’s ability to learn from the labeled presence of diagnosis codes and infer probable but uncoded cases acknowledges the selective and non-random nature of medical coding. This method provides probabilistic estimates that align closely with expert chart reviews, suggesting a powerful tool for bridging the recognition gap in mental health documentation. The model identifies subtle indicators scattered through medical records, including risk factors, patterns of injury, and behaviors consistent with self-harm, which traditional coding may overlook.

Praveen Kumar, the first author, elucidated that these unrecorded patterns often remain buried within clinician notes, hidden from the structured data fields scrutinized by algorithms and reviewers alike. The study successfully validated only the pattern where self-harm was documented in narrative form yet uncoded. However, the broader challenge includes uncovering instances where self-harm is inferred indirectly through associated conditions and treatment patterns—a frontier requiring patient engagement and integration of data beyond the EHR.

This research signifies a collaborative triumph, pooling interdisciplinary expertise from medical informatics, psychiatry, computer science, economics, and statistics across multiple institutions, including the Raymond G. Murphy VA Medical Center and Vanderbilt University. The convergence facilitated the creation of a robust analytical framework designed to address real-world clinical data challenges. It highlights how precision in measuring mental health histories can enhance suicide prevention efforts, augment clinical decision-making, and enrich the scientific foundation for public health interventions.

The study aligns with a larger research initiative aimed at revealing under-documented conditions within medical records using positive-and-unlabeled learning methodologies. Previously, the team applied similar techniques to identify under-coded opioid use disorder, and ongoing projects extend this paradigm to other elusive conditions such as PTSD, depression, bipolar disorder, and sleep disorders. These endeavors collectively aim to expose the “hidden morbidity” that conventional medical data infrastructures frequently miss.

While the PULSNAR approach is not yet intended for frontline clinical deployment due to validation requirements and ethical considerations, its potential to complement existing suicide and overdose reporting tools is evident. By offering a scalable, data-driven lens that compensates for the known limitations of standardized coding systems, it equips healthcare organizations to identify patients with documented but obscure histories of self-harm more reliably. This, in turn, could streamline targeted interventions and resource deployment.

In an era where mental health crises are escalating, and healthcare systems grapple with increasingly complex data ecosystems, this research underscores the necessity of harnessing innovative computational techniques to reveal critical insights hidden in plain sight. The strategic integration of machine learning with clinical expertise exemplifies a vital path forward—transforming the overwhelming volume of clinical data into actionable knowledge that enhances patient safety and care quality.

Ultimately, these findings challenge the status quo, urging a paradigm shift in how healthcare frameworks capture and utilize mental health information. Dr. Lambert poignantly reflects on this systemic challenge, stating that self-harm history “matters too much to stay buried in records that are not practical to review line by line during routine care.” The researchers’ work offers a beacon for a future where technology augments human judgment, enabling clinicians and researchers to fully comprehend and address the realms of mental health that have long been shrouded by limitations in documentation and data accessibility.

Subject of Research: People

Article Title: Detecting Uncoded Self-Harm in Veterans’ Electronic Health Records Using Positive and Unlabeled Learning: Retrospective Cohort Study

News Publication Date: 4-Jun-2026

Web References:

• Journal of Medical Internet Research article
• DOI: 10.2196/89071
• PULSNAR Method Explanation

Keywords: Computer modeling, self-harm, electronic health records, machine learning, positive-unlabeled learning, mental health documentation, Veterans Health Administration, health informatics

Leading the charge, Dr. Neal Chatterjee and his team at the University of Washington School of Medicine have harnessed the combined power of machine learning and clinical data to create predictive models that could potentially alter clinical practice. Published in the esteemed journal JACC: Advances, the research employed a vast dataset encompassing nearly 1.7 million patient records from a large integrated healthcare system in the U.S., encompassing both EHR data and 12-lead EKGs. The team’s approach leverages three distinct AI models: one informed solely by EKG waveforms, another utilizing structured EHR inputs comprising more than 150 clinical variables, and a third hybrid model integrating both data sources.

The methodology underpinning the model development was rigorous, stratified across three patient cohorts to ensure robustness and real-world applicability. Initially, the training cohort consisted of 993 out-of-hospital cardiac arrest cases alongside 5,479 age- and sex-matched control subjects without cardiac events, spanning nearly a decade from 2013 to 2021. This comprehensive dataset allowed the AI to discern subtle patterns and predictors embedded in both the electrical signatures of the heart and broader health parameters that correlate with increased SCA risk.

Validation proceeded with a testing cohort from more recent years (2022-2023), which included 463 cardiac arrest incidents and nearly 3,000 controls. Application of the AI models here confirmed their predictive fidelity, with the models reliably distinguishing high- and low-risk profiles congruent with training findings. However, the true test came from applying the tools to a real-world cohort: a large, unfiltered group of nearly 40,000 individuals who had undergone EKG testing in 2021 regardless of pre-existing conditions, followed longitudinally for two years to see who eventually suffered cardiac arrest.

Remarkably, the integrated EHR-EKG AI model correctly identified 153 of the 228 patients who experienced cardiac arrest as high-risk, exhibiting an enrichment in risk prediction that elevated from a baseline of 1 in 1,000 to 1 in 100. This degree of stratification could be transformative in clinical settings, alerting healthcare practitioners and patients alike to a risk magnitude impactful enough to prompt preemptive clinical decisions and potentially lifesaving interventions.

Notably, the EKG-only model – which depends solely on the analysis of the heart’s electrical activity – demonstrated impressive prognostic capability independently, showing only a modest decrease in performance compared to models incorporating the full range of EHR data. Given the global ubiquity and low cost of 12-lead EKG machines, this finding unlocks practical pathways for broad implementation of risk screening even outside advanced healthcare environments.

Beyond cardiovascular parameters traditionally associated with SCA, the AI models illuminated novel risk factors often overlooked in clinical practice. These included electrolyte imbalances, substance use behaviors, and adverse medication interactions, highlighting how multifaceted cardiac arrest triggers can be. This insight suggests that AI-driven risk alerts might encourage clinicians to systematically review modifiable patient factors and perform more nuanced, preventive care tailored to the individual’s comprehensive clinical profile.

Despite this promise, Dr. Chatterjee and his collaborators underscore that predictive power alone is insufficient without clear clinical pathways. The next frontier is refining post-prediction responses: determining which diagnostic tests, monitoring regimens, or therapeutic interventions should follow identification of elevated risk. Clarifying these management strategies is paramount to translating AI prediction into tangible reductions in SCA incidence and mortality.

Another caveat relates to the study’s data source—all drawn from a single healthcare system—raising questions about the generalizability of the models to demographically or geographically distinct populations. Additionally, the real-world cohort limitation to individuals who had undergone EKG testing introduces selection bias; patients not receiving EKGs, who might nonetheless be at risk, remain outside the model’s purview. Furthermore, concerns about AI model biases linked to healthcare disparities and demographic representation warrant careful ongoing evaluation to ensure equitable, unbiased application across diverse patient populations.

The research, funded by prestigious entities including the National Institutes of Health, the American Heart Association, the European Union, and the Foundation Leducq, represents a multi-institutional collaborative success involving Massachusetts General Hospital and the Broad Institute at MIT and Harvard. The confluence of clinical cardiology expertise, data science innovation, and vast patient data has created an unprecedented predictive toolset with the potential to radically change how sudden cardiac arrest is anticipated and perhaps eventually prevented.

Dr. Chatterjee points to an exciting era ahead where artificial intelligence transforms the interpretation of routine medical tests from static snapshots into dynamic, predictive analyses capable of forewarning life-threatening events. This evolution heralds a future in which the frustration and tragedy of sudden cardiac arrest—long an enigmatic killer striking without warning—may become significantly mitigated through enhanced data-driven foresight integrated seamlessly into everyday clinical workflows worldwide.

Subject of Research: People
Article Title: Artificial Intelligence-Enhanced Electrocardiography and Health Records to Predict Cardiac Arrest
News Publication Date: 11-May-2026
Web References: DOI: 10.1016/j.jacadv.2026.102787
Keywords: Cardiac arrest, Artificial intelligence, Electrocardiography, Electronic medical records, Computer modeling

A groundbreaking study from Duke Health harnesses the power of AI to analyze routine electronic health records (EHRs) and estimate the risk of ADHD well before conventional clinical diagnosis occurs. The study, published in Nature Mental Health, dives deep into the wealth of clinical data accumulated in primary care settings. Researchers developed a sophisticated AI model trained on EHR data from more than 140,000 children, effectively unlocking hidden patterns across developmental, behavioral, and clinical parameters from birth through early childhood.

This AI-based predictive model is not a diagnostic instrument per se but functions as a risk stratification tool. It sifts through vast repositories of medical histories, identifying subtle, intricate interplays of variables that often presage an eventual ADHD diagnosis. Importantly, the model exhibits high predictive accuracy from the age of five onwards, maintaining robust performance across diverse demographics including sex, race, ethnicity, and insurance status. This generalizability marks a significant advance over previous attempts that often struggled with bias or limited datasets.

The transformative potential of such an AI-driven approach lies in its capacity to propel ADHD assessment into a proactive phase rather than reactive recognition. Typically, children with ADHD are diagnosed only after years of behavioral challenges and academic struggles. Early risk estimation equips pediatricians and primary care providers with actionable alerts, empowering them to closely monitor at-risk children and initiate timely referrals for comprehensive diagnostic evaluations by specialists.

Elliot Hill, the study’s lead author and a data scientist at Duke’s Department of Biostatistics & Bioinformatics, emphasizes the untapped richness of electronic health records. The AI effectively distills complex clinical narratives into predictive insights, demonstrating that everyday medical data can yield powerful prognostic signals that were previously inaccessible. Rather than creating an AI “doctor,” the model serves as an assistive technology aimed at optimizing clinician workflow and resource allocation.

Matthew Engelhard, M.D., Ph.D., the study’s senior author, underscores that automated tools like this could prevent many children from “falling through the cracks.” By spotlighting those who are at heightened risk, clinicians can allocate more focused attention and deploy evidence-based interventions sooner, which is strongly correlated with enhanced academic and psychosocial outcomes.

From a technical perspective, the AI model employs advanced machine learning techniques capable of integrating vast multidimensional data points, including developmental milestones, recorded behavioral issues, comorbid medical conditions, and even patterns indicating healthcare utilization. This holistic analysis leverages longitudinal data, allowing the system to discern trajectories rather than relying on static snapshots, which greatly enhances prediction accuracy.

Despite these promising results, the researchers caution that the AI tool requires further validation before widespread clinical adoption. Rigorous prospective studies and real-world trials are necessary to assess effectiveness, safety, and ethical implications. Additionally, integration within existing healthcare infrastructures presents logistical challenges, including data standardization, patient privacy considerations, and interoperability with diverse EHR systems.

Naomi Davis, Ph.D., an associate professor in the Department of Psychiatry and Behavioral Sciences and co-author, highlights the critical importance of connecting at-risk families with timely, evidence-based supports. Early identification must be paired with adequate resources and interventions tailored to each child’s unique needs, or else the benefits of predictive technology risk being lost.

This research aligns with a larger movement harnessing AI to predict and understand mental health risks across the lifespan. Hill and Engelhard have contributed additional studies exploring AI applications in adolescent mental illness, illustrating a growing commitment to integrating computational models into psychiatric epidemiology and personalized medicine.

The study benefits from robust funding by the National Institute of Mental Health and the National Center for Advancing Translational Sciences, signaling strong institutional support for leveraging AI as a transformative force in medical diagnostics. As the field continues to innovate, such AI-driven models may soon be integral to pediatric care, enabling clinicians to anticipate disorders like ADHD with unprecedented precision and intervene at life-changing early stages.

In summary, this pioneering work demonstrates that AI tools analyzing routine clinical data can efficiently predict ADHD risk long before traditional diagnoses arise. By embedding such technologies into everyday healthcare workflows, there is a distinct possibility of drastically transforming outcomes and quality of life for millions of children worldwide, delivering on the promise of precision medicine tailored from the very start of life.

Subject of Research: Early prediction of attention-deficit/hyperactivity disorder (ADHD) risk in children through artificial intelligence analysis of electronic health records

Article Title: Artificial Intelligence Models Predict Childhood ADHD Risk Years Before Diagnosis Using Routine Electronic Health Records

News Publication Date: April 27, 2026

Web References: https://www.nature.com/articles/s44220-026-00628-2

Image Credits: Duke Health / Shawn Rocco

Keywords

Attention-deficit/hyperactivity disorder, ADHD, artificial intelligence, AI, electronic health records, EHR, pediatric medicine, early diagnosis, machine learning, neurodevelopmental disorders, predictive modeling, mental health

Central to this study is the demonstration that genetic ancestry profoundly impacts how patients respond to therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for weight loss and type 2 diabetes. The researchers found that therapeutic efficacy of GLP-1 drugs, such as semaglutide, varies significantly across different ancestral populations, and critically, this variability correlates with individuals’ genetic risk scores for type 2 diabetes. Such findings underscore the limitations of one-size-fits-all treatment approaches and herald a new era where genetic insights inform tailored medical interventions.

Utilizing integrative proteogenomic analyses, the team pinpointed a key genetic association between response to semaglutide and the gene PTPRU. This gene had not previously been linked to GLP-1 drug response, offering compelling evidence for its role in modulating treatment outcomes. Proteomics data from patients undergoing GLP-1 therapy further reinforced these findings, providing a molecular bridge between genotypic variation and phenotypic drug responsiveness. This discovery paves the way for future mechanistic studies and the potential development of predictive biomarkers to optimize obesity and diabetes therapies.

The ATLAS Biobank uniquely encompasses an expansive representation of ancestries, reflecting Los Angeles’ unparalleled ethnic diversity. Participants hail from five continental ancestries and encompass thirty-six fine-scale ancestry groups, including communities historically underrepresented in genetic research such as Armenian, Ashkenazi Jews, Iranian Jewish, Filipino, and Mexican American populations. This breadth allows for the disentanglement of genetic influences on health outcomes without confounding by healthcare system disparities, a common challenge when comparing data across institutions.

Historically, the majority of genomic studies have disproportionately sampled populations of European descent, limiting the applicability of findings to the global population and exacerbating health disparities. The UCLA ATLAS initiative confronts this bias head-on by drawing from one of the world’s most ancestrally diverse metropolitan areas—Los Angeles County—which boasts over 9.6 million residents. By integrating diverse genetic data with longitudinal clinical records within a single health system, this study establishes a paradigm for equitable precision medicine research.

Beyond common genetic variants, the study pioneers examination of rare variants within specific ancestry groups, unveiling hitherto unknown genetic correlations with disease phenotypes. For instance, the gene ANKZF1 was linked to peripheral vascular disease among African ancestry individuals, while EPG5 was associated with lipid metabolism traits such as HDL cholesterol and triglyceride levels in Ashkenazi Jewish participants. These discoveries highlight the importance of including rare variant analyses in multi-ancestry cohorts to illuminate genetic contributions to complex diseases.

The investigation also delineated ancestry-specific susceptibilities to adverse drug reactions. Among Mexicans and South Americans, increased vulnerability to negative hormonal therapy effects was observed, reinforcing the need for ancestry-informed pharmacovigilance. This awareness is critical for improving drug safety profiles and optimizing treatment plans for diverse populations, thereby enhancing patient outcomes and reducing health inequities.

A further significant dimension of the research involves polygenic risk scores (PRS), composite metrics summarizing genetic predispositions to diseases based on numerous variants spread across the genome. Within the ATLAS cohort, PRS demonstrated promising predictive power for conditions like type 1 diabetes, with a substantial proportion of patients exhibiting elevated scores matching their clinical diagnoses. Though clinical translation remains in early stages, these findings position PRS as a valuable tool for stratifying patient risk and guiding preventive strategies.

The researchers’ focus on GLP-1 receptor agonists as a case study showcases how genetic diversity can influence response to commonly prescribed medications. GLP-1 drugs, including branded agents such as Ozempic and Wegovy, have revolutionized treatment for obesity and diabetes but exhibit variable efficacy among individuals. Identifying genetic markers like those in PTPRU provides a molecular rationale for this heterogeneity and suggests pathways to develop predictive algorithms to personalize therapy.

Importantly, the UCLA Health system’s comprehensive real-world data environment—linking genetics with electronic health records—affords robust insights into disease pathogenesis and therapeutic outcomes within a clinical context. This approach contrasts with isolated laboratory investigations, elevating the translational potential of discoveries. As Dr. Daniel Geschwind, senior associate dean of Precision Health at UCLA, notes, ATLAS’s integration of broad and fine-scale ancestries illuminates genetic factors overlooked in earlier studies focused on broad ancestral categories alone.

Already, the ATLAS Biobank supports a public web portal presenting thousands of heritable genetic associations across diverse populations, enabling researchers worldwide to access and build upon these unprecedented data. With over 259,000 participants consented and 157,000 biospecimens collected since its launch in 2016, this initiative embodies a scalable model for genomic medicine research embedded within large health systems, fostering health equity by design.

The implications of these findings extend far beyond the academic sphere. They propel precision medicine closer to practical application, where individual genomic profiles guide risk assessment, diagnosis, and personalized treatments. Furthermore, this study is a call to action emphasizing the necessity of inclusive genetic research that respects and reflects population diversity to fulfill the promise of equitable, effective healthcare for all.

In conclusion, the UCLA Health-led study published in Cell underscores the transformative impact of integrating genetic diversity, clinical data, and molecular biology within a single health ecosystem. It highlights novel genetic determinants influencing disease risk and drug response, particularly in relation to type 2 diabetes and weight loss medications. By bridging gaps in ancestry representation and leveraging comprehensive real-world data, the work sets a new standard for precision health discovery and clinical translation, demonstrating that personalized medicine is not just a possibility for some but an achievable goal for the global population.

Subject of Research: Human tissue samples
Article Title: Advancing Precision Health Discovery in a Genetically Diverse Health System
News Publication Date: 27-Mar-2026
Web References: [UCLA ATLAS Community Health Initiative Biobank Web Portal] (link not provided in source)
References: DOI: 10.1016/j.cell.2026.03.007
Keywords: precision medicine, genetic diversity, GLP-1 receptor agonists, type 2 diabetes, polygenic risk scores, ancestry, genetic associations, semaglutide, pharmacogenomics, health disparities, rare genetic variants, proteomics

Suicide remains one of the foremost public health challenges among veterans receiving care within the Veterans Affairs (VA) health system. Traditional risk assessment tools, often reliant on structured clinical data and self-report questionnaires, have struggled with sensitivity and specificity issues. This limitation impedes early detection and intervention efforts, which are crucial for preventing suicide attempts. The newly introduced methodology capitalizes on advancements in computational linguistics, enabling more sophisticated analysis of clinical narratives, patient-provider communication, and other unstructured textual data embedded within electronic health records.

Natural language processing, a subfield of artificial intelligence, involves teaching computers to comprehend and interpret human language. While prior suicide risk prediction models have incorporated NLP, this study distinctively integrates multiple discrete NLP models, each specialized in capturing different linguistic and contextual dimensions. By doing so, the researchers overcome the pitfalls inherent in singular models that might overlook subtle but critical indicators expressed in natural language. This multi-model ensemble approach adeptly synthesizes diverse textual features to construct a comprehensive risk profile tailored for individual patients.

Central to this innovation is the recognition that suicide risk factors manifest in complex, multifactorial patterns within clinical notes and correspondences. Some models focus on sentiment analysis to detect emotional distress, while others evaluate temporal shifts in language indicative of worsening mental states or emerging suicidal ideation. Additional models examine semantic coherence, allowing the system to discern disorganized thought patterns linked to psychiatric conditions. The fusion of these discrete analytic perspectives empowers the predictive framework to transcend the constraints of conventional assessment paradigms.

To develop and validate their approach, the research team accessed an extensive corpus of VA patient records, meticulously anonymized to safeguard privacy. Their dataset encompassed millions of clinical notes spanning outpatient visits, hospitalizations, and mental health consultations. The diverse linguistic expressions across varying contexts presented both a challenge and an opportunity; however, by training discrete NLP models on tailored subsets of this data, the system achieved remarkable adaptability. This adaptability is pivotal given the heterogeneous nature of language used by patients and clinicians across different care settings.

Importantly, the model’s performance metrics demonstrated significant improvements over existing benchmarks. Predictive accuracy, measured by area under the receiver operating characteristic curve (AUC), surged substantially, signaling better identification of patients at imminent risk of suicide. Moreover, the system showed an enhanced capacity for early detection, flagging risk signals weeks or even months before traditional methods. This temporal advantage opens new avenues for preventive care strategies, optimizing resource allocation and fostering proactive clinical decision-making.

Beyond methodological rigor, the study underscores the ethical imperatives entwined with deploying AI-driven risk prediction tools in psychiatry. The researchers advocate for transparent model interpretability, ensuring that clinicians understand the basis for risk assessments. Such transparency is vital to maintaining trust and facilitating meaningful dialogue between patients and healthcare providers. Furthermore, the study emphasizes the necessity of continuous model evaluation to mitigate biases, especially critical when serving a demographically diverse veteran population with varying linguistic and cultural backgrounds.

The implications of this research extend far beyond the VA healthcare system. Mental health providers worldwide confront similar challenges in suicide prevention, particularly in managing large volumes of unstructured clinical data. The successful demonstration of integrating discrete NLP models suggests a scalable blueprint adaptable to other healthcare environments. Future iterations of such systems may incorporate additional data streams, including patient-generated texts, social media activity, or physiological sensors, further enriching the predictive landscape.

The study also prompts reflection on the evolving role of artificial intelligence in human-centered care. While technology enhances predictive capabilities, it is not a substitute for the empathy and nuanced judgment provided by mental health professionals. Instead, AI-powered tools should be viewed as augmentative, equipping clinicians with deeper insights without supplanting the critical human dimension of care. The researchers envision collaborative frameworks where AI and clinicians operate synergistically to formulate personalized, timely, and effective intervention plans.

Looking ahead, the research team is exploring pathways to integrate their models into real-time clinical workflows. Such integration necessitates overcoming operational challenges, including seamless interfacing with existing electronic health record systems, ensuring data security, and establishing protocols for alert management. The ultimate goal is to embed these predictive tools within routine patient care, rendering suicide risk assessment both continuous and dynamic rather than a sporadic, subjective endeavor.

Moreover, the study ignites exciting prospects for interdisciplinary collaboration. By bringing together experts in computational linguistics, psychiatry, bioinformatics, and healthcare policy, the team demonstrates the power of convergent approaches in tackling complex mental health crises. This synergy is crucial for translating technological innovations into tangible improvements in patient outcomes, especially in vulnerable populations such as veterans, who face unique stressors related to combat exposure, reintegration challenges, and comorbidities.

The enhancement of personalized suicide risk prediction through discrete NLP models represents a paradigm shift in mental health analytics. It embodies a broader transformation where AI not only processes big data but interprets it in contextually rich, clinically meaningful ways. Such advanced analysis fosters earlier, more accurate identification of high-risk individuals, enabling interventions that are timely, targeted, and potentially life-saving. As suicide rates continue to pose alarming public health concerns, innovations like these offer a beacon of hope.

As the technology matures, ongoing research will be critical to assess real-world effectiveness, patient acceptance, and cost-benefit ratios. Ethical oversight, patient privacy, and the prevention of unintended consequences such as stigmatization remain paramount considerations. However, this pioneering work signals a promising trajectory toward harnessing AI’s full potential in mental healthcare, ultimately contributing to reduced suicide incidence and improved well-being among veterans and beyond.

In conclusion, the integration of multiple discrete natural language processing models heralds a new era in suicide risk prediction, offering profound enhancements in accuracy and personalization. This sophisticated approach unlocks the latent informational wealth embedded in clinical text, transforming it into actionable clinical intelligence. As we embrace these advanced computational tools, we move closer to realizing a healthcare paradigm that is not only data-informed but profoundly human-centric—saving lives through science and empathy intertwined.

Subject of Research: Enhancing suicide risk prediction in veterans through integrative natural language processing models

Article Title: Enhancing personalized suicide risk prediction for VA patients by integrating discrete natural language processing models

Article References:

Dimambro, M., Levy, J., Gui, J. et al. Enhancing personalized suicide risk prediction for VA patients by integrating discrete natural language processing models.
Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03940-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03940-8

Traditionally, cardiometabolic risk prediction algorithms have been developed with the general population in mind, often targeting middle-aged or older adults. This approach has inherently neglected the unique physiological and lifestyle factors prevalent in younger cohorts, especially those grappling with psychosis. PsyMetRiC 2.0 bridges this divide by utilizing a refined algorithm, honed through the rigorous analysis of anonymized health data from over 25,000 young people with psychosis in the United Kingdom, whose clinical trajectories were tracked longitudinally over two decades.

The methodology employed is a landmark in predictive modeling: by harnessing real-world electronic health records, researchers created a model capable of predicting three critical outcomes. Within one year, it estimates significant weight gain; over six years, the onset of metabolic syndrome; and within ten years, the development of type 2 diabetes. These outcomes were chosen not merely for their clinical relevance but also for their resonance with patient priorities, ensuring the tool’s recommendations are grounded in shared decision-making principles.

What differentiates PsyMetRiC’s approach is its conscientious design for utility and fairness. It was rigorously validated across multiple international cohorts, including populations in Spain, Switzerland, Finland, the Netherlands, Canada, Hong Kong, and Australia, demonstrating robust predictive performance beyond the UK. Furthermore, the designers incorporated feedback from clinicians, carers, and those with lived experience of psychosis, in partnership with organizations such as the McPin Foundation and The Centre for Mental Health. This collaborative process ensured that the tool not only delivers precise risk assessments but also communicates these risks in a manner that is accessible, culturally sensitive, and motivating for patients.

At the core of PsyMetRiC 2.0’s architecture is advanced statistical analysis and machine learning techniques applied to large-scale, longitudinal datasets. By identifying complex interactions between demographic factors, clinical presentations, medication regimens—particularly antipsychotic-induced metabolic side effects—and lifestyle parameters like diet, exercise, and smoking, the algorithm provides personalized risk profiles. The predictive models incorporate both fixed and dynamic variables, accounting for changes in health status over time, which enhances their clinical relevance in monitoring disease progression and guiding timely interventions.

A significant achievement of PsyMetRiC is its certification by the UK Medicines & Healthcare products Regulatory Agency (MHRA) as a Class 1 Medical Device. This regulatory endorsement is historic within psychiatry, underscoring the tool’s safety, efficacy, and readiness for integration into routine clinical workflows. Its deployment offers a paradigm shift, encouraging clinicians to move beyond reactive care and towards proactive, prevention-oriented strategies tailored to the complex needs of young people with severe mental illness.

The clinical implications of deploying PsyMetRiC extend beyond individual patient outcomes. People living with psychosis experience substantially reduced life expectancy, averaging a 15-year gap compared to the general population, predominantly due to preventable cardiometabolic diseases. Early identification of risk allows for the initiation of lifestyle modifications and pharmacological treatments—such as metformin or statins—aimed at mitigating weight gain and metabolic disturbances. The availability of a quantifiable risk score also facilitates nuanced conversations between healthcare providers and patients, helping dismantle barriers related to health literacy and stigma.

Emphasizing patient engagement, PsyMetRiC’s risk reports are multifaceted, incorporating numeric probabilities alongside graphical visualizations, ranging from traditional risk charts to innovative ‘heart age’ analogues. This multimodal communication strategy caters to diverse patient preferences and cognitive styles, enhancing comprehension and fostering behavior change. Importantly, educational materials co-produced with individuals with lived experience accompany the application, guiding clinicians on optimal risk discussion techniques to maximize impact.

The research underpinning PsyMetRiC 2.0 is published in the highly regarded journal The Lancet Psychiatry, signaling its scientific rigor and clinical significance. The study employed retrospective multicohort analysis with sophisticated data/statistical methods, ensuring that the model’s validations are both methodologically sound and clinically applicable. Planned future directions include refining the algorithm using results from ongoing qualitative and health economic evaluations, as well as expanding its validation in non-UK populations, including forthcoming trials in the United States.

The developers recognize that health inequities are embedded within many datasets, potentially propagating bias in predictive models. By actively seeking to test and correct for such biases, PsyMetRiC represents an important step toward equitable healthcare delivery. The tool aims to serve patients from diverse ethnic and socioeconomic backgrounds, addressing disparities that have historically marginalized these groups in physical health management.

In summary, PsyMetRiC 2.0 embodies a convergence of advanced analytics, patient-centered design, and regulatory validation, poised to revolutionize the management of cardiometabolic risk in young people with psychosis. Its introduction marks a pivotal moment in psychiatric medicine, promising to reduce premature mortality through early, personalized intervention. As this tool gains traction in clinical settings, it holds the potential to reshape how mental and physical health intersect in vulnerable populations globally.

Subject of Research: People
Article Title: Cardiometabolic prediction models for young people with psychosis spectrum disorders in the UK (PsyMetRiC 2.0): a retrospective, multicohort clinical prediction model study
News Publication Date: 11-Mar-2026
Web References:

• PsyMetRiC Web Application: https://psymetric.app/
• Lancet Psychiatry Article: https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00398-0/fulltext
  References:
• Perry, B. et al., “Cardiometabolic prediction models for young people with psychosis spectrum disorders in the UK (PsyMetRiC 2.0),” The Lancet Psychiatry, 2026.
• Original PsyMetRiC Validation Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC8211566/
  Keywords: Psychotic disorders, Cardiometabolic risk, Metabolic syndrome, Type 2 diabetes, Obesity, Machine learning, Health equity, Psychiatry, Predictive modeling

Eligibility criteria form the bedrock of clinical trial enrollment, dictating which patients may or may not participate based on intricate clinical, demographic, and sometimes genomic data. Traditionally, this process has been laborious, tediously conducted by skilled clinical research coordinators and physicians manually reviewing patient records. The sheer volume of data, combined with the complex medical language and nuanced clinical context embedded within EHRs, can produce substantial delays and errors in patient selection. These inefficiencies invariably slow trial recruitment and prolong the time necessary to advance promising oncology therapies to market.

The study takes advantage of retrospectively curated EHRs, applying a randomized controlled trial design to evaluate the combinatorial power of AI and human judgment. Advanced natural language processing (NLP) algorithms transformed unstructured clinical notes and structured data into standardized formats interpretable by machine learning models. These AI systems were trained to pre-screen patients rapidly against multifaceted protocol eligibility rules, identifying candidates with a high probability of meeting trial inclusion criteria. Crucially, the AI output was then reviewed by human clinical experts who could confirm, override, or refine selections, blending the speed of computation with nuanced human insight.

Results from this hybrid screening framework defied traditional assumptions that machines alone suffice or that human effort alone is superior. Instead, the team demonstrated significant gains in accuracy and efficiency through their human-AI teaming approach. Compared to manual prescreening, the combined method more effectively sifted through potentially eligible patients, reducing false positives and negatives alike. This led to not only quicker patient identification but also better allocation of clinical research resources, minimizing unnecessary follow-up assessments on ineligible candidates.

Technologically, the backbone of the AI system involved cutting-edge deep learning architectures optimized for clinical text mining. Applying transformer-based models, fine-tuned on domain-specific corpora, enabled the extraction of complex clinical concepts relevant to oncology protocols. The researchers emphasized the importance of interpretability, providing clinicians with transparent rationale behind AI-generated eligibility flags. This interpretability fostered trust among human reviewers, an essential factor ensuring adoption of AI tools in sensitive decision-making processes.

Beyond efficiency, ensuring equitable patient selection emerged as a key benefit of the human-AI synergy. Traditionally, human bias and cognitive overload can inadvertently skew screening towards subsets of patients, risking underrepresentation of minorities or rare clinical phenotypes. The AI’s standardized evaluation criteria helped to mitigate unintended screening biases, while humans provided contextual awareness to prevent exclusion of borderline cases that might be unjustly disregarded by rigid algorithms.

The implications of this research extend far beyond oncology. The scalable human-AI team-based prescreening framework promises transformative impact across numerous clinical domains where eligibility criteria are complex and data voluminous—a common challenge in cardiovascular disease trials, infectious disease studies, and neurology as well. The marriage of AI’s data-processing speed with human judgment’s contextual granularity could redefine clinical trial workflows universally.

However, the journey to integration is not without hurdles. The authors note that successful deployment necessitates seamless integration with clinical informatics infrastructures, robust data privacy protections, and ongoing training of AI systems to adapt to evolving trial protocols and populations. Additionally, regulatory acceptance of AI-assisted screening processes remains an evolving landscape requiring transparent validation and auditability.

This study epitomizes the future of modern clinical trials in an era increasingly dominated by Big Data and AI. By thoughtfully combining the strengths of human cognition and machine intelligence, Parikh and colleagues have paved a path toward more rapid, equitable, and reliable patient enrollment. Their work captures not merely a technical achievement but a paradigm shift in clinical research methodologies—ushering in a new generation of precision trial design empowered by human-AI collaboration.

As clinical trials remain fundamental to discovering novel cancer treatments and improving patient outcomes globally, this advancement could expedite breakthroughs that save lives. It resolves a critical bottleneck in the clinical development pipeline, enabling scientists and clinicians to focus less on onerous manual screening and more on therapeutic innovation and patient care.

Looking ahead, further research is anticipated to explore refining AI models to incorporate real-time patient updates, social determinants of health, and patient-reported outcomes into eligibility assessments. Integration with digital biomarkers and wearables could enrich data inputs, empowering even more personalized, dynamic trial matching. Moreover, the ethical, legal, and social implications of AI-human partnerships in clinical research will warrant continued dialogue among stakeholders to ensure responsible and equitable technology use.

Ultimately, this landmark investigation illustrates that the future of clinical trials lies not in choosing between humans or machines but in harnessing the distinct advantages of both. The synergy unleashed by human-AI teaming stands as a beacon for transformative clinical research innovation, offering new hope for speeding development of life-saving cancer therapies worldwide.

Subject of Research: Human-AI collaboration for improving accuracy and efficiency in eligibility prescreening for oncology clinical trials using retrospective electronic health records.

Article Title: Human-AI teaming to improve accuracy and efficiency of eligibility criteria prescreening for oncology trials: a randomized evaluation trial using retrospective electronic health records.

Article References:

Parikh, R.B., Kolla, L., Beothy, E.A. et al. Human-AI teaming to improve accuracy and efficiency of eligibility criteria prescreening for oncology trials: a randomized evaluation trial using retrospective electronic health records.
Nat Commun (2026). https://doi.org/10.1038/s41467-026-68873-8

Image Credits: AI Generated